Navigation Links
Sosei Announces Filing of NDA for SOH-075 (NorLevo(R)) in Japan
Date:9/30/2009

TOKYO, September 30 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced the submission of the New Drug Application (NDA) for the emergency contraceptive pill SOH-075 (NorLevo(R)) to Ministry of Health, Labour and Welfare (MHLW) by Sosei Co. Ltd., its wholly owned Japanese subsidiary.

NorLevo(R) is an oral emergency contraceptive "morning after pill" which is used to prevent unwanted pregnancy after unprotected intercourse. NorLevo(R) contains only levonorgestrel as an active ingredient. The dosing is started within 72 hours after unprotected sexual intercourse.

Sosei has acquired the exclusive distribution rights to the product in Japan from HRA Pharma. The NDA is supported by the data from Phase III study that was successfully completed in October 2008.

Editor's Notes:

About Sosei

Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

SOURCE Sosei Group Corporation


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
2. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
3. Sosei Announces Outcome of Strategy Review
4. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
5. EPA announces research strategy to study nanomaterials
6. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
7. MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System
8. Axial Biotech Announces Commercial Availability of SCOLISCORE(TM) AIS Prognostic Test
9. Alexandria Real Estate Equities, Inc. Announces Public Follow-on Offering of 3,000,000 Shares of Common Stock
10. Spherix Incorporated Announces Annual Shareholders Meeting Date
11. Compendia Bioscience Announces the Release of Oncomine 4 Research Edition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... 03, 2016 , ... Microbial genomics leader uBiome is awarding ... been made to Dr. Renato Polimanti of Yale University School of Medicine, who ... Grant proposals have been vetted by the company’s scientific review committee. , ...
(Date:12/2/2016)... ... 2016 , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing ... President, Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski ... and Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
(Date:12/2/2016)... ... 2016 , ... ACEA Biosciences, Inc. announced today that it will be presenting ... the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... trials for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR ...
Breaking Biology Technology:
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 ... is one of the most crucial aspects of recovery so we need to do ... serious health risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... friends sleep and find a Christmas present that could help them to manage their ... ...
(Date:11/28/2016)... "The biometric system market projected to ... system market is in the growth stage and is ... biometric system market is expected to be valued at ... 16.79% between 2016 and 2022. Government initiative in adoption ... rising use of biometric technology in financial institutes and ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, a ... for public safety, investigation, corrections and monitoring, announced today ... competitor, ICSolutions, to have an independent technology judge determine ... most modern high tech/sophisticated telephone calling platform, and the ... that they do most of what we do – ...
Breaking Biology News(10 mins):